BC Regenacy

Beijing 3E-Regenacy Pharmaceuticals Co., Ltd. (BC Regenacy) is a joint venture established by Regenacy and 3E Bioventures. BC Regenacy will obtain the exclusive license for Regenacy's lead compound, ricolinostat [an orally administered selective histone deacetylase 6 (HDAC6) inhibitor], for use by patients with peripheral neuropathy in mainland China, Hong Kong, and Macao.